Axol’s iPSC-derived cells are robust and reproducibly made, making them the perfect tool for your assay development requirements.
Human Relevant Cardiotox with iPSC-Derived Cardiomyocytes
Pre-clinical cardiotoxicity testing is being transformed by CiPA-validated iPSC-derived cardiomyocytes
Quality, robust human iPSC-derived cells for cardiotoxicity testing
The Comprehensive in vitro Pro-Arrhythmia Assay (CiPA) initiative was introduced to develop a new strategy for assessing cardiac safety of compounds in vitro.
Axol’s human iPSC-derived cardiomyocytes are CiPA-validated, making them a suitable model for screening compounds for cardiotoxicity.
Reach out to learn more about our iPSC-derived cardiomyocytes, and the in house services we offer to aid your R&D